...Jun-Yi Wu; Zhen-Xin Zeng; Yi-Nan Li; Zhi-Bo Zhang; Shao-Wu Zhuang; Bin Li; Jian-Yin Zhou; Shu-Qun Li; De-Yi Liu; Han Li; Xiang-Ye Ou; Jia-Yi Wu; Mao-Lin Yan Introduction: Accurately predicting the outcomes of conversion therapy among patients with initially unresectable hepatocellular carcinoma...

... advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements. 2025 Hepatocellular carcinoma Regorafenib...

... hyperplasia (FNH) or FNH-like nodules were evaluated histologically and sequenced for a panel of 50 genes using next-generation sequencing. Results: Thirty-eight nodules from 17 patients with CPSS were histologically classified as hepatoblastomas ( n = 2), hepatocellular carcinomas ( n = 4), HNF-1α...

..., instructions or products referred to in the content or advertisements. 2024 Hepatocellular carcinoma Lenvatinib Pembrolizumab LEAP-012 Transarterial chemoembolization The results of the LEAP-012 trial were presented at the European Society for Medical Oncology (ESMO) 2024 [ 1...

...; Masayuki Kurosaki; Kazushi Numata; Kung-Kai Kuo; Yilei Mao; Yih-Jyh Lin; Kangshun Zhu; Philip Twumasi-Ankrah; Javeed Khan; Maria Awan; Kirhan Ozgurdal; Shukui Qin Introduction: In the phase 3 RESORCE trial, regorafenib prolonged overall survival (OS) in patients with unresectable hepatocellular carcinoma...

... to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements. 2024 Hepatocellular carcinoma Early detection Biomarker Methylation Diagnostic accuracy Dear Editor, We read with great interest the article by Kunimune et...

... immune checkpoint inhibitors (ICIs) may improve recurrence-free survival (RFS) in patients with hepatocellular carcinoma (HCC). This study evaluated the effects of adjuvant ICI treatment duration on RFS and overall survival (OS) among patients with HCC at high risk of recurrence. Methods: The RFS and OS...

...Yanze Lin; Rexiati Ruze; Ruiqing Zhang; Talaiti Tuergan; Maolin Wang; Alimu Tulahong; Dalong Zhu; Zhongdian Yuan; Tiemin Jiang; Tuerganaili Aji; Yingmei Shao Background: CD8 + T cells are critical for the oncogenesis and progression of the hepatocellular carcinoma (HCC) tumor microenvironment...

...: The phase 3 LEAP-002 study (NCT03713593) of advanced hepatocellular carcinoma (HCC) suggested improved antitumor activity of lenvatinib plus pembrolizumab versus lenvatinib alone with manageable safety, although overall survival (OS) and progression-free survival (PFS) did not reach prespecified statistical...

...Yu-Yun Shao; Andrei R. Akhmetzhanov Introduction: Immune checkpoint inhibitors (ICIs) are fundamental in treating advanced hepatocellular carcinoma (HCC). Considering previous reports implied varied responses among patient subgroups, such as patients with different hepatitis etiologies, we planned...

... stage hepatocellular carcinoma (HCC), although its outcomes vary. This study aimed to identify imaging biomarkers of immunotherapy susceptibility linked to gadoxetic acid-enhanced magnetic resonance imaging (EOB-MRI) and immune phenotypes, particularly immune-excluded phenotypes, with a tumor immune...

..., including hepatocellular carcinoma (HCC). However, there is a glaring gap in the research landscape concerning the understanding of what cancer-free status truly means for advanced-stage HCC. Our study sheds light on the profound implications of reaching a cancer-free by radiologic assessments in patients...

..., instructions or products referred to in the content or advertisements. 2024 Hepatocellular carcinoma Atezolizumab + bevacizumab Adjuvant immunotherapy Recurrence of hepatocellular carcinoma (HCC) after resection or ablation is extremely common, with a recurrence rate of 70–80% at 5...

... Doctor Association Background: Hepatocellular carcinoma (HCC) is one of the most common malignant tumors in China. Most HCC patients have the complications of chronic liver disease and need overall consideration and whole-course management, including diagnosis, treatment, and follow-up. To develop...

...Xinyu Bi; Yinying Lu; Bo Chen; Zhengqiang Yang; Zhixian Hong; Hanping Wang; Yongkun Sun; Xiaodong Wang; Chunwang Yuan; Daobing Zeng; Zhen Huang; Aiping Zhou; Wen Zhang; Shunda Du; Jianjun Zhao; Jianguo Zhou; Yirui Zhai; Xu Che; Hong Zhao; Haitao Zhao; Jianqiang Cai Hepatocellular carcinoma (HCC...

... or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements. 2024 Hepatocellular carcinoma Magnetic resonance imaging Microvascular invasion Recurrence and survival Surgery Dear Editor, We read with great interest the article...

...Heechul Nam; Pil Soo Sung; Sung Won Lee; Do Seon Song; Jung Hyun Kwon; Jeong Won Jang; Chang Wook Kim; Si Hyun Bae Introduction: Despite its prognostic impact, nutritional status has not yet been integrated into the assessment of hepatocellular carcinoma (HCC). This study investigated...

... the efficacy and safety of high-dose stereotactic body radiation therapy (SBRT) with an extended (48 h or more) interfraction interval for hepatocellular carcinoma (HCC) ≤5 cm in size after incomplete response to transarterial chemoembolization (TACE). Methods: This multicenter prospective study included 54...

...; Jason P.E. Chang; Brian K.P. Goh; Han Chong Toh; Pierce K.H. Chow Introduction: Transarterial radioembolisation (RE) using yttrium-90 (Y-90) microspheres is a widely used locoregional therapy for a broad spectrum of hepatocellular carcinoma (HCC) given its favourable safety profile. We evaluated...

...Bin Xu; Lu-Na Wang; Zi-Yi Wang; Tian He; Xiao-Dong Zhu; Ying-Hao Shen; Jian Zhou; Jia Fan; Hui-Chuan Sun; Cheng Huang Introduction: Surgical resection following systemic therapy is feasible in patients with initially unresectable hepatocellular carcinoma (HCC). However, postoperative tumor...